Anzeige
Mehr »
Login
Donnerstag, 26.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9BV | ISIN: DK0061031895 | Ticker-Symbol: 8VY
Stuttgart
23.12.24
13:42 Uhr
0,006 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCANDION ONCOLOGY A/S Chart 1 Jahr
5-Tage-Chart
SCANDION ONCOLOGY A/S 5-Tage-Chart

Aktuelle News zur SCANDION ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.08.Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S368As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra Hamnen Corporate...
► Artikel lesen
18.07.Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3184At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 3 -------------------------------------- Short...
► Artikel lesen
18.07.Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2198At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 2 -------------------------------------- Short...
► Artikel lesen
11.07.Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology373At the request of Scandion Oncology, the last trading day in Scandion Oncology's paid subscription units will be changed from 2024-07-11 to 2024-07-15. Instrument: Paid subscription units...
► Artikel lesen
04.06.Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of Scandion Oncology370With effect from June 05, 2024, the subscription units in Scandion Oncology will be traded on First North Growth Market. Trading will continue up until and including June 17, 2024. Instrument:...
► Artikel lesen
31.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024370Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024 The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment...
► Artikel lesen
SCANDION ONCOLOGY Aktie jetzt für 0€ handeln
23.05.Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue223On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry...
► Artikel lesen
22.05.Scandion Oncology A/S: Scandion Oncology - Interim Report Q1 2024126Scandion Oncology (Scandion) today announces its Interim Report Q1 2024. The following is taken from the report. Francois Martelet, CEO:"Results from the CORIST Phase IIa trial have demonstrated impressive...
► Artikel lesen
13.05.Scandion Oncology A/S: Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101254Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX...
► Artikel lesen
28.02.Scandion Oncology A/S: Scandion Oncology - Q4 & yearend report 2023128Scandion Oncology (Scandion) today announces its Q4 & yearend report 2023. The following is taken from the report. Francois Martelet, CEO:"Completion of and very positive topline results from part 3...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1